mosunetuzumab (bispecific antibody component)
E902883
CD20-directed CD3 T-cell engager
anticancer drug
biologic medicinal product
bispecific monoclonal antibody
therapeutic antibody
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| mosunetuzumab (bispecific antibody component) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074426 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: mosunetuzumab (bispecific antibody component) Context triple: [CD20 protein, targetOf, mosunetuzumab (bispecific antibody component)]
-
A.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
-
B.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
E.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: mosunetuzumab (bispecific antibody component) Target entity description: Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
-
A.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
-
B.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
E.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
CD20-directed CD3 T-cell engager
ⓘ
anticancer drug ⓘ biologic medicinal product ⓘ bispecific monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsOnCellType |
B lymphocytes
ⓘ
T lymphocytes ⓘ |
| adverseEffect |
cytokine release syndrome
ⓘ
fatigue ⓘ headache ⓘ hypophosphatemia ⓘ infections ⓘ neutropenia ⓘ pyrexia ⓘ tumor flare ⓘ |
| belongsTo |
CD20-targeted therapies
ⓘ
T-cell redirecting therapies ⓘ |
| bindsTo |
CD20-expressing B cells
ⓘ
T cells via CD3 ⓘ |
| effectOnBCells | B-cell depletion ⓘ |
| effectOnImmuneSystem | T-cell activation ⓘ |
| hasAdministrationPattern | step-up dosing to mitigate cytokine release syndrome risk ⓘ |
| hasEffect | reduction of tumor burden in responsive B-cell malignancies ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasStructureFeature | bispecific binding domains for CD20 and CD3 ⓘ |
| hasTarget |
CD20
ⓘ
linked to:
CD20 protein
CD3 ⓘ
linked to:
CD3 complex
|
| immuneEffect |
forms immunologic synapse between T cells and B cells
ⓘ
promotes perforin and granzyme-mediated apoptosis of target B cells ⓘ |
| indication | treatment of certain B-cell malignancies ⓘ |
| isNot |
CAR T-cell therapy
ⓘ
chemotherapy ⓘ |
| isUsedAs | monotherapy in certain indications ⓘ |
| mechanismOfAction |
induces T cell–mediated cytotoxicity
ⓘ
redirects T cells to kill CD20-positive B cells ⓘ |
| pharmacologicalClass | bispecific T-cell engager antibody ⓘ |
| regulatoryStatus | approved for treatment of relapsed or refractory follicular lymphoma in adults ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
signs and symptoms of cytokine release syndrome ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetExpressionRequirement | requires CD20 expression on malignant B cells ⓘ |
| therapeuticArea | hematologic oncology ⓘ |
| treats |
relapsed or refractory B-cell non-Hodgkin lymphoma
ⓘ
relapsed or refractory follicular lymphoma ⓘ |
| usedIn | adult patients ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: mosunetuzumab (bispecific antibody component) Description of subject: Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.